Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy; Liver Diseases

Treatments: Drug: Afatinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT01298063

1200.86

2010-021140-18 (EudraCT Number)

Details and patient eligibility

About

Up to 38 subjects entered with the aim of entering 8 subjects with mild liver impairment (at highest dose of afatinib), 8 subjects with moderate liver impairment (at either highest dose or two lower doses) and 8 healthy matched controls to each of this two groups.

Enrollment: 35 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects:

1. Healthy males and females according to a complete medical history, including a physical examination, vital signs (Blood Pressure, Pulse Rate), 12-lead Electrocardiogram, and clinical laboratory tests. The healthy subjects must meet the matching criteria based on the matching approach (cf. Section 3.3).

2. Age =18 and =75 years

3. Body Mass Index =18.5 and =34 kg/m2

4. Creatinine clearance >70 mL/min according to Cockroft & Gault (for healthy volunteers, cf. Section 10.2)

5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation. Hepatically impaired subjects as determined by a hepatologist/ gastroenterologist:

6. Male and female liver impaired subjects determined by results of screening classified as Child-Pugh A; Child-Pugh score of 5-6 points or as Child-Pugh B; Child-Pugh score of 7-9 points, cf. Section 10.2. Child-Pugh criteria must be stable for at least 3 months prior to screening and during the trial.

7. Age =18 and =75 years

8. Body Mass Index =18.5 and =34 kg/m2

9. Creatinine clearance >40 mL/min according to Cockroft & Gault (for liver impaired subjects, cf. Section 10.2)

10. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation.

    For all females:

11. Postmenopausal female subjects (postmenopausal defined as at least 1 year of spontaneous amenorrhea [in questionable cases or spontaneous amenorrhea below 1 year a blood sample with simultaneous follicle stimulating hormone (FSH) above 40 IU/l and estradiol below 30 ng/l is confirmatory]) or adequate contraception* for female subjects of childbearing potential during the study and until 2 months after study completion, e.g. any of the following: implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence for at least 1 month prior to first study drug administration, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent or surgically sterile have to use an additional barrier method (e.g. condom).

Exclusion criteria

Any relevant deviation from healthy conditions (excluded conditions caused by liver impairment)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 3 patient groups

Afatinib Group A, B (2), D

Experimental group

Description:

healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib

Treatment:

Drug: Afatinib

Drug: Afatinib

Drug: Afatinib

Afatinib Group B (3), D

Experimental group

Description:

healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib

Treatment:

Drug: Afatinib

Drug: Afatinib

Drug: Afatinib

Afatinib Group B (1), D

Experimental group

Description:

healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib

Treatment:

Drug: Afatinib

Drug: Afatinib

Drug: Afatinib